RxDoctor Payments DataLook up a doctor →

Richard Kim, MD

Hematology & Oncology · Tampa, FLNPI 1609810779

Payments from drug & device makers

$8,495,935in general payments, 2019–2025

Across 1,302 payments — averaging $6525.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.9M
  • Bayer$1.2M
  • GSK$549K
  • Tersera Therapeutics LLC$531K
  • AstraZeneca$420K
  • Pfizer$413K
  • plus $1.5M from 45 others
$3,396in research payments, 2019–2025

Across 4 payments — averaging $849.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Servier Pharmaceuticals LLC$296

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck164$3,875,867
Bayer195$1,192,969
GSK74$549,384
Tersera Therapeutics LLC92$530,595
AstraZeneca56$419,688
Pfizer58$413,083
Genentech, Inc.40$395,137
E.r. Squibb & Sons, L.L.C.14$208,289
Eisai Inc.79$144,906
Incyte Corporation129$139,557
Janssen Research & Development, LLC19$134,731
Taiho Oncology, Inc.72$71,597
Lexicon Pharmaceuticals, Inc.4$66,780
Blueprint Medicines Corporation18$65,838
EMD Serono, Inc.3$50,563
Exelixis Inc.64$38,435
AbbVie22$28,524
Array Biopharma Inc28$26,099
Servier Pharmaceuticals LLC17$25,133
Lilly USA, LLC17$21,235
Astrazeneca UK Limited4$18,087
Novartis1$14,127
Ipsen Biopharmaceuticals, Inc27$13,913
Genentech USA, Inc.17$11,773
Takeda Pharmaceuticals U.S.A., Inc.9$11,297
Agios Pharmaceuticals, Inc.9$5,710
Pharmacosmos Therapeutics Inc.11$5,179
Partner Therapeutics, Inc.11$4,608
Jazz Pharmaceuticals Inc.5$4,088
Boehringer Ingelheim1$2,220
Sanofi-aventis U.S. LLC1$1,568
Coherus Oncology, Inc.1$1,200
Medtronic8$1,026
Seagen Inc.7$372
Foundation Medicine, Inc.3$280
Intera Oncology, Inc2$258
Daiichi Sankyo Inc.2$245
Helsinn Therapeutics (U.S.), Inc.3$204
Cardiovascular Systems Inc.2$198
Caris MPI, Inc.1$164
Deciphera Pharmaceuticals Inc.1$159
Novocure Inc.1$136
Boston Scientific1$136
Amgen1$109
Gilead1$108
Baxter Healthcare1$103
Angiodynamics, Inc.1$75
Beone Medicines USA, Inc.1$64
Servier Bioinnovation1$50
Covidien LP2$47
Aimmune Therapeutics, Inc.1$23

How this compares

$8,495,935 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$34,276
Medicare patients
161
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →